SCHEMBL2660596

SCHEMBL2660596

COc1cccc(Cl)c1-c1cccc2c(N)c3c(nc12)CN(C1=CC=C1)C3=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 2/20 0.35
▸ HSP90AB1 P08238 1/20 0.35
▸ SIK2 Q9H0K1 1/20 0.34
▸ DPP4 P27487 3/20 0.33
▸ ACHE P22303 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ GABRA2 P47869 1/20 0.33
▸ WEE1 P30291 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657233 0.89 GABRA1 (0.43) KMT2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL2655753 0.89 UGCG (0.39) DPP4ACHEKMT2AGABRG2GABRB3
SCHEMBL2658032 0.87 UGCG (0.33) ACHEKMT2AGABRA1GABRG2GABRB3
SCHEMBL2661383 0.86 CYP3A4 (0.34) DPP4ACHEKMT2AGABRA1GABRG2
SCHEMBL2655981 0.85 CRHR1 (0.38) DPP4KMT2AGABRA1GABRG2GABRB3
SCHEMBL2660107 0.84 ALDH1A1 (0.36) HSP90AA1HSP90AB1ACHEKMT2AGABRG2
SCHEMBL2657086 0.84 UGCG (0.36) KMT2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL2658318 0.84 GABRG2 (0.37) DPP4GABRA1GABRG2GABRB3GABRA5
SCHEMBL2657791 0.83 GABRG2 (0.43) KMT2AGABRG2GABRB3GABRA2MEN1
SCHEMBL2660785 0.83 GABRG2 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF HSP90AA1 4097/4885HSP90AB1 4007/4885SIK2 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback